Connect with us

News

Start-up raises US$25m to develop treatment for PCOS-related infertility

The treatment works by lowering androgen production, which can restore ovulation in women with PCOS

Published

on

The medical device start-up May Health has raised US$25m in funding to develop an “innovative” treatment to restore ovulation in women with PCOS.

PCOS is one of the most common causes of female infertility, affecting 10 per cent of women globally.

In women with PCOS, there is a local disregulation of androgens as compared to oestrogens in the ovary, leading to inconsistent ovulation.

The condition is also associated with increased insulin resistance, Type 2 diabetes, heart disease and stroke.

May Health’s investigational treatment works by lowering androgen production, which can restore ovulation.

The one-time in-office procedure aims to induce ovulation through targeted ablation of ovarian tissue using radiofrequency energy.

The financing round, co-led by Bpifrance and Trill Impact, is hoped to advance the company’s therapy through a clinical study which will evaluate the treatment’s potential to address PCOS-related infertility.

“This financing allows May Health to continue delivering upon our mission to become a leader in global women’s health and transform treatment for patients with PCOS,” Anne Morrissey, CEO of May Health, told Femtech World.

“We are very grateful to each of the investors who have continued to support us on our journey to offer more for women living with PCOS, an area of medicine that has been underserved with few treatment options.

“There has been a severe unmet need for more accessible options, and this new funding will allow us to continue to advance our US pivotal study to investigate the potential of Ovarian Rebalancing in women with infertility caused by PCOS.”

She added: “We’re committed to bringing a modern approach to the millions of women looking for alternative options to achieve pregnancy in a more natural manner.”

Dr Robert Auerbach, OB/GYN and chairman of the May Health board, said: “For years, women with PCOS who struggle with infertility have sought alternative treatment options that go beyond IVF and laparoscopic ovarian drilling.

“Our team is working to develop a simple and safe procedure that can activate natural ovulation and help women regain their ability to grow their families.

“We’re thankful to our investment partners for their support and look forward to further research of Ovarian Balancing in the REBALANCE Study.”

Nina Rawal, co-head and partner at Trill Impact Ventures, shared: “We see May Health as a great example of a company where commercial opportunity and impact go hand in hand.

“Trill Impact is excited to collaborate with the May Health team and its strong shareholders to bring their innovative product to women who have suffered from a lack of treatment options for too long.”

Jean-François Morin, investment director at Bpifrance, said May Health is charting a “new path” in fertility care.

“We are thrilled to support the company’s effort to bring its new approach to women with PCOS, including advancing it in the pivotal REBALANCE Study,” he explained.

“With its unique mechanism of action, May Health’s device has the potential to significantly improve the lives of patients with PCOS, including but not limited to related infertility issues.

“We are committed to supporting May Health to become a leader in the PCOS space.”

To receive the Femtech World newsletter, sign up here.

News

Labcorp launches screening test to identify preeclampsia risk sooner

The new screening tool is capable of assessing the risk of preeclampsia sooner, the test maker says

Published

on

Labcorp has launched a screening test that can assess the risk of preeclampsia before 34 weeks of pregnancy.

Preeclampsia is a high blood pressure disorder that can develop during pregnancy or postpartum and is a leading cause of maternal morbidity and mortality worldwide.

Roughly one in 25 pregnancies in the US is affected by preeclampsia, which poses an even greater risk for non-Hispanic black women, who experience the condition at a 60 per cent higher rate compared to white women.

In January, Labcorp announced the launch and availability of an FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia during the second and third trimesters.

The first trimester test uses four early pregnancy biomarkers to provide a risk assessment with up to 90 per cent sensitivity, nearly twice the sensitivity of assessing typical maternal history or biophysical factors alone.

According to Labcorp, the test results provide risk identification earlier than traditional symptoms, such as hypertension or protein in the urine, which tend to develop around 20 weeks gestation.

Eleni Tsigas, chief executive officer of the Preeclampsia Foundation, said: “Our organisation celebrates this innovative new test offering.

“Research shows that patients and providers want access to more tools that better predict progression to preeclampsia, especially for those patients with low- to average-risk or those with first-time pregnancies for whom there is some uncertainty.”

Dr Brian Caveney, chief medical and scientific officer at Labcorp, added: “Labcorp is committed to advancing maternal and foetal health through innovative diagnostic and screening solutions.

“This new first trimester blood test is another significant milestone in our mission to improve health and improve lives. By giving healthcare providers another tool to assess preeclampsia risk in their pregnant patients with objective biomarkers, we’re helping to advance prenatal care and improve outcomes for mothers and their babies.”

Continue Reading

News

People with HIV can be sperm and egg donors

A change in law will allow people with non-transmissible HIV in the UK to donate gametes to partners

Published

on

Same-sex couples with non-transmissible HIV will now be able to donate eggs or sperm and become parents.

People with HIV will able to donate their sperm or eggs to their partners, as the law in the UK is updated.

The Human Fertilisation and Embryology Act will be amended via a statutory instrument to allow people with non-transmissible HIV – with a viral load low enough not to pass on – to donate eggs or sperm, known as gametes, as part of fertility treatment to their partners.

Under current rules on IVF, only a male partner with HIV can give their sperm to their female partner and not to anyone else.

The law change will also eliminate extra screening costs for female same-sex couples undertaking reciprocal IVF treatment.

The government says this is part of wider work to improve access to IVF for everyone and ensure same-sex couples have the same rights as a man and woman when trying to conceive.

“These changes will allow more people to fulfil their dream of becoming parents,” said UK health minister, Maria Caulfield.

“We have changed the law to ensure equality for people living with HIV when accessing IVF, allowing them to donate their eggs and sperm.

“In addition, the change will allow female same-sex couples to access IVF with no extra screening costs, the same as heterosexual couples.”

She added: “These changes will help create a fairer system by removing barriers to accessing fertility care as we have set out in the Women’s Health Strategy.”

The changes to the law will allow people with HIV to donate their gametes to family, friends and known recipients.

The regulations include an updated definition of partner donation to enable female same-sex couples wishing to donate eggs to each other to undergo the same testing requirements as heterosexual couples.

Under current rules, female same-sex couples hoping to conceive via reciprocal IVF must first go through screening for syphilis and genetic screening, such as cystic fibrosis, which can cost over £1,000, while heterosexual couples do not need to undergo this screening.

Julia Chain, chair of the Human Fertilisation and Embryology Authority (HFEA), said: “The HFEA welcomes the news that legislation regarding partner donation in relation to reciprocal IVF, and gamete donation from those who have HIV with an undetectable viral load, has now been proposed in Parliament.

“Fertility treatment is helping more people than ever to create their family, and everyone undergoing fertility treatment should be treated fairly.

“For known donation from individuals with undetectable HIV, we anticipate that the first clinics may be able to begin to offer this treatment around 3 months following a change in the law.

“We encourage any patients or donors who may be affected by these changes to visit the HFEA website to find out free and impartial information, including about how to choose a fertility clinic.”

Minister for equalities, Stuart Andrew MP, added: “Treatment for HIV has improved significantly, saving countless lives, but the stigma surrounding it persists – a stigma which often prevents people from getting tested and seeking treatment.

“These changes will help to reduce that stigma, making it clear that people with HIV can live full and happy lives. I am delighted by these changes which will enable more people to experience the joy of becoming parents.”

Continue Reading

News

Portfolia invests total of US$65m into women’s health companies

The platform has invested in 47 femtech start-ups to date

Published

on

Trish Costello, founder and CEO of Portfolia

The US venture investing platform Portfolia has announced it has invested a total of US$65m into women’s health companies and solutions.

Portfolia aims to create, educate and support the largest community of women investors in the world.

The company says it was amongst the first to recognise the “immense” potential of women’s wealth, with women’s health at the forefront.

To date, Portfolia has made investments in 112 companies with 47 of those women’s health companies being femtech and active aging specific.

Some of these include Madison Reed, Maven, Everly Health, Bone Health, Veana, Your Choice, Future Family, Willow, Hey Jane, Lighthouse Pharma, L-Nutra and JoyLux.

The total companies Portfolia has invested in are estimated to serve over 102 million customers in 115 countries worldwide.

These companies have a combined value of over US$17bn, with over US$1bn in revenue and 10,000 employees worldwide.

According to Portfolia, almost 70 per cent of these businesses are led by female CEOs, and 49 per cent are led by BIPOC individuals.

“At Portfolia, we believe in the power of activating our wealth for returns and impact,” said Trish Costello, founder and CEO of Portfolia.

“Today, women in the United States have unprecedented access to wealth – with over US$25tn of wealth in the US and almost 50 per cent of it owned by women.

“This wealth is power – power to create financial change and invest in the companies and businesses that matter to us and meet our needs/desires.”

She added: “Our commitment goes beyond traditional venture capital – we’re pioneering change, saving lives, and creating opportunities for all, while creating the most powerful community of women investors globally, and the first to activate our wealth to shape the future of healthcare.”

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.